The health economic benefits to individual substance users and to society of substance use disorder (SUD) treatment and hepatitis C (HCV) and HIV treatment of substance users need to be evaluated and communicated to decision makers in terms that are relevant to the diverse systems in which care is delivered. Researchers need better support, including skills and infrastructure, to effectively disseminate their economic findings in the evolving health policy environment. The overall aim of CHERISH (Center for Health Economics of TReatment Interventions for Substance Use Disorder, HCV, and HIV) is to develop and disseminate economic evidence that informs substance use treatment policy and HCV and HIV care of substance users, and to increase the impact of this research by addressing the needs of integrated healthcare system providers and payers. In support of this aim, the CHERISH Dissemination and Policy Core will have a unique combination of expertise in the theory and practice of dissemination research, understanding of national health economic policy both broadly and specifically relating to treatment of SUD and related conditions, clinical experience in SUD treatment, and experience identifying and convening stakeholders and engaging them in constructive dialogue with health economics researchers. The Policy and Dissemination Core?s specific aims are 1) to translate and disseminate health economic research results to key stakeholders for SUD, HCV, and HIV treatment decisions, and 2) to enhance the relevance and impact of Center research by assessing stakeholder needs for economic information on SUD, HCV, and HIV treatment of substance users and by working with researchers to refine the relevance of their research and findings. We will repackage research results for target policy audiences and push this content through traditional and new media channels, and we will develop a network of relevant stakeholders and share content through stakeholder conferences, face-to- face meetings, and policy roundtables. We will conduct an in-depth assessment of the needs of decision makers for economic information to make informed SUD, HCV, and HIV treatment decisions. Based on the needs identified, we will work with Center researchers to anticipate the specific policy relevance of their results while their research is in progress in order to plan for dissemination of their findings and design future research. We will work with the Methodology Core to assist it in promoting economic evaluation methods, translating these methods for decision makers, and promoting harmonization of economic data collection tools. We will work closely with the HCV and HIV Core to disseminate and translate the results of HCV and HIV longitudinal data analyses and simulation modeling. We will collaborate with the Pilot Grant and Training Core to evaluate and mentor pilot projects relating to dissemination science, to provide intensive training and mentoring of pilot grant awardees, and to conduct introductory in-person and web-based training in dissemination methods and practices.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
5P30DA040500-05
Application #
9692586
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
2020-11-30
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Delgado, M Kit; Shofer, Frances S; Patel, Mitesh S et al. (2018) Association between Electronic Medical Record Implementation of Default Opioid Prescription Quantities and Prescribing Behavior in Two Emergency Departments. J Gen Intern Med 33:409-411
Rodriguez, Carla V; Rubenstein, Kevin B; Linas, Benjamin et al. (2018) Increasing hepatitis C screening in a large integrated health system: science and policy in concert. Am J Manag Care 24:e134-e140
Shelton, Brittany A; Berdahl, Gideon; Sawinski, Deirdre et al. (2018) Optimal Timing of Hepatitis C Treatment among HIV/HCV Co-infected ESRD Patients: Pre vs. Post-Transplant. Am J Transplant :
Schechter-Perkins, Elissa M; Miller, Nancy S; Hall, Jon et al. (2018) Implementation and Preliminary Results of an Emergency Department Nontargeted, Opt-out Hepatitis C Virus Screening Program. Acad Emerg Med :
McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531
Kapadia, Shashi N; Johnston, Carrie D; Marks, Kristen M et al. (2018) Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity. J Public Health Manag Pract :
Bachhuber, Marcus A; Saloner, Brendan; LaRochelle, Marc et al. (2018) Physician Time Burden Associated with Querying Prescription Drug Monitoring Programs. Pain Med 19:1952-1960
McCollister, Kathryn; Baumer, Pamela; Davis, Monica et al. (2018) Economic Evaluation of the Juvenile Drug Court/Reclaiming Futures (JDC/RF) Model. J Behav Health Serv Res 45:321-339
Freiman, J Morgan; Jacobson, Karen R; Muyindike, Winnie R et al. (2018) Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr 77:405-412
Kapadia, Shashi N; Jeng, Philip J; Schackman, Bruce R et al. (2018) State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals. Clin Infect Dis 66:1618-1620

Showing the most recent 10 out of 93 publications